Irene M Ghobrial

List of Publications by Year
in descending order

313 papers	10,095 citations	38742 50 h-index	42399 92 g-index
318 all docs	318 docs citations	318 times ranked	12476 citing authors

#	Article	IF	Citations
1	Clonal hematopoiesis is associated with increased risk of progression of asymptomatic WaldenstrÃ¶m macroglobulinemia. Blood Advances, 2022, 6, 2230-2235.	5.2	10
2	Attenuated response to SARS-CoV-2 vaccine in patients with asymptomatic precursor stages of multiple myeloma and Waldenstrom macroglobulinemia. Cancer Cell, 2022, 40, 6-8.	16.8	11
3	Single-cell profiling of tumour evolution in multiple myeloma â€" opportunities for precision medicine. Nature Reviews Clinical Oncology, 2022, 19, 223-236.	27.6	58
4	The emerging importance and evolving understanding of clonal hematopoiesis in multiple myeloma. Seminars in Oncology, 2022, 49, 19-26.	2.2	5
5	Quality of life, psychological distress, and prognostic perceptions in patients with multiple myeloma. Cancer, 2022, 128, 1996-2004.	4.1	12
6	Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study. Lancet Haematology,the, 2022, 9, e340-e349.	4.6	27
7	Mass cytometry staining for human bone marrow clinical samples. STAR Protocols, 2022, 3, 101163.	1.2	1
8	The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood, 2022, 140, 1229-1253.	1.4	512
9	Perspectives on the Risk-Stratified Treatment of Multiple Myeloma. Blood Cancer Discovery, 2022, 3, 273-284.	5.0	24
10	Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. New England Journal of Medicine, 2022, 387, 132-147.	27.0	173
11	Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes. Nature Communications, 2022, 13, .	12.8	11
12	B-PRISM (Precision Intervention Smoldering Myeloma): A phase II trial of combination of daratumumab, bortezomib, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma.. Journal of Clinical Oncology, 2022, 40, 8040-8040.	1.6	0
13	Progression signature underlies clonal evolution and dissemination of multiple myeloma. Blood, 2021, 137, 2360-2372.	1.4	26
14	Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With WaldenstrÃ¶m Macroglobulinemia. Journal of Clinical Oncology, 2021, 39, 565-575.	1.6	98
15	Single-cell RNA sequencing: one step closer to the clinic. Nature Medicine, 2021, 27, 375-376.	30.7	20
16	ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow Microenvironment. Blood Cancer Discovery, 2021, 2, 338-353.	5.0	8
17	Inflammatory stromal cells in the myeloma microenvironment. Nature Immunology, 2021, 22, 677-678.	14.5	4
18	Perceptions of prognosis in caregivers of multiple myeloma (MM) patients.. Journal of Clinical Oncology, 2021, 39, 12082-12082.	1.6	0

#	Article	IF	Citations
19	Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated WaldenstrÃ¶m macroglobulinemia. Blood, 2021, 138, 1535-1539.	1.4	32
20	Abstract 2240: Genomic profiling of smoldering multiple myeloma classifies distinct molecular groups. , 2021, , .		0
21	Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration. Clinical Cancer Research, 2021, 27, 5195-5212.	7.0	26
22	The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma. Transplantation and Cellular Therapy, 2021, 27, 807-816.	1.2	3
23	Quality of Life, Psychological Distress, and Prognostic Awareness in Patients with Multiple Myeloma. Blood, 2021, 138, 4082-4082.	1.4	0
24	A Randomized Placebo-Controlled Phase 2 Study of Metformin for the Prevention of Progression of Monoclonal Gammopathy of Undetermined Significance and Low Risk Smoldering Multiple Myeloma. Blood, 2021, 138, 1659-1659.	1.4	0
25	B-PRISM (Precision Intervention Smoldering Myeloma): A Phase II Trial of Combination of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma. Blood, 2021, 138, 4782-4782.	1.4	0
26	A Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma. Blood, 2021, 138, 2749-2749.	1.4	2
27	Single Cell Characterization of Myeloma and Its Precursor Conditions Reveals Transcriptional Signatures of Early Tumorigenesis. Blood, 2021, 138, 2219-2219.	1.4	0
28	Quality of Life, Psychological Distress, and Prognostic Awareness in Caregivers of Patients with Multiple Myeloma. Blood, 2021, 138, 3044-3044.	1.4	1
29	Identification of a Novel Epigenetic Mechanism of MYC Deregulation in Smoldering and Newly Diagnosed Multiple Myeloma Patients. Blood, 2021, 138, 504-504.	1.4	1
30	Single-Cell Multi-Omics Defines the Cell-Type Specific Impact of SF3B1 Splicing Factor Mutations on Hematopoietic Differentiation in Human Clonal Hematopoiesis and Myelodysplastic Syndromes. Blood, 2021, 138, 145-145.	1.4	3
31	Non-Invasive Liquid Biopsy to Quantify and Molecularly Characterize Circulating Multiple Myeloma Cells in the Assessment of Precursor Disease Pathology. Blood, 2021, 138, 78-78.	1.4	1
32	A Phase II Study of Daratumumab in Patients with High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma. Blood, 2021, 138, 1649-1649.	1.4	2
33	Clonal Hematopoiesis Prevalence Increases throughout Treatment of Newly Diagnosed Multiple Myeloma Patients. Blood, 2021, 138, 1091-1091.	1.4	1
34	Clonal Hematopoiesis Is Associated with Increased Risk of Progression of Asymptomatic WaldenstrÃ¶m Macroglobulinemia. Blood, 2021, 138, 2678-2678.	1.4	1
35	Regular Aspirin Use and Mortality in Multiple Myeloma Patients. Cancer Epidemiology Biomarkers and Prevention, 2021, , cebp.EPI-21-0946-E.2021.	2.5	1
36	A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma. Clinical Cancer Research, 2020, 26, 344-353.	7.0	66

#	Article	IF	Citations
37	Pregnancy outcomes, risk factors, and cell count trends in pregnant women with essential thrombocythemia. Leukemia Research, 2020, 98, 106459.	0.8	16
38	Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development. Cell, 2020, 183, 1714-1731.e10.	28.9	163
39	Pro-organic radical contrast agents (â€œpro-ORCAsâ€) for real-time MRI of pro-drug activation in biological systems. Polymer Chemistry, 2020, 11, 4768-4779.	3.9	20
40	BELLINI: a renaissance for an era of precision therapy in multiple myeloma. Lancet Oncology, The, 2020, 21, 1547-1549.	10.7	5
41	The COronavirus Pandemic Epidemiology (COPE) Consortium: A Call to Action. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1283-1289.	2.5	34
42	The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19â€“infected patients. Blood, 2020, 135, 1912-1915.	1.4	253
43	Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nature Communications, 2020, 11, 2996.	12.8	98
44	Monoclonal Gammopathy of Undetermined Significance (MGUS)â€”Not So Asymptomatic after All. Cancers, 2020, 12, 1554.	3.7	22
45	Intensification and consolidation therapy in multiple myeloma in the current era. Lancet Haematology,the, 2020, 7, e427-e429.	4.6	1
46	Genome instability in multiple myeloma. Leukemia, 2020, 34, 2887-2897.	7.2	63
47	Bone marrow niches in haematological malignancies. Nature Reviews Cancer, 2020, 20, 285-298.	28.4	270
48	Prediagnosis dietary pattern and survival in patients with multiple myeloma. International Journal of Cancer, 2020, 147, 1823-1830.	5.1	27
49	Genomic Landscape of WaldenstrÃ¶m Macroglobulinemia and Its Impact on Treatment Strategies. Journal of Clinical Oncology, 2020, 38, 1198-1208.	1.6	103
50	Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. Nature Cancer, 2020, 1, 493-506.	13.2	209
51	Clinical Controversies in the Management of Smoldering Multiple Myeloma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 314-319.	3.8	4
52	Dissecting racial disparities in multiple myeloma. Blood Cancer Journal, 2020, 10, 19.	6.2	79
53	Single-Cell Multi-Omics in Human Clonal Hematopoiesis Reveals That DNMT3A R882 Mutations Perturb Early Progenitor States through Selective Hypomethylation. Blood, 2020, 136, 1-2.	1.4	1
54	Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. Journal of Clinical Oncology, 2020, 38, 2380-2389.	1.6	110

#	Article	IF	Citations
55	Quantified Morphology in Diagnosis of Hematologic Malignancies. , 2020, 17, .		0
56	The Moving Target of When to Treat on the Myeloma Spectrum. , 2020, 17, .		0
57	Bispecific Antibodies in Multiple Myeloma: Do These T cell-Recruiting Antibodies Make a Difference?. , 2020, 17, .		0
58	Promising Preclinical Results for Immunotherapy in Multiple Myeloma. , 2020, 17, .		0
59	A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma: Results from Phase I Dose Escalation Cohorts. Blood, 2020, 136, 1-2.	1.4	0
60	A Next Generation Liquid Biopsy Approach for Multiple Myeloma. Blood, 2020, 136, 33-33.	1.4	0
61	Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma. Leukemia, 2019, 33, 266-270.	7.2	21
62	Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma. American Journal of Hematology, 2019, 94, 1244-1253.	4.1	42
63	Mitochondrial metabolism promotes adaptation to proteotoxic stress. Nature Chemical Biology, 2019, 15, 681-689.	8.0	275
64	A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and WaldenstrÃ¶m Macroglobulinemia. Clinical Cancer Research, 2019, 25, 4907-4916.	7.0	36
65	Dietary Pattern and Risk of Multiple Myeloma in Two Large Prospective US Cohort Studies. JNCI Cancer Spectrum, 2019, 3, pkz025.	2.9	33
66	Monoclonal gammopathy of undetermined significance. Blood, 2019, 133, 2484-2494.	1.4	57
67	Immunotherapy in Multiple Myeloma: Accelerating on the Path to the Patient. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, 332-344.	0.4	16
68	Bone marrow biopsy in lowâ€risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group. American Journal of Hematology, 2019, 94, E146-E149.	4.1	11
69	Citron Rho-interacting kinase silencing causes cytokinesis failure and reduces tumor growth in multiple myeloma. Blood Advances, 2019, 3, 995-1002.	5.2	15
70	Bone marrow niche in multiple myeloma and its precursor states. HemaSphere, 2019, 3, 121-123.	2.7	1
71	Antibody-targeting of ultra-small nanoparticles enhances imaging sensitivity and enables longitudinal tracking of multiple myeloma. Nanoscale, 2019, 11, 20485-20496.	5.6	27
72	A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma. Clinical Cancer Research, 2019, 25, 478-486.	7.0	29

#	Article	IF	Citations
73	Fluorescence monitoring of rare circulating tumor cell and cluster dissemination in a multiple myeloma xenograft model in vivo. Journal of Biomedical Optics, 2019, 24, 1.	2.6	25
74	Pregnancy Outcomes, Risk Factors, and Gestational Cell Count Trends in Pregnant Women with Essential Thrombocythemia and Polycythemia Vera. Blood, 2019, 134, 4172-4172.	1.4	6
75	Updated Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVd-lite) in Transplant-Ineligible Multiple Myeloma. Blood, 2019, 134, 3178-3178.	1.4	17
76	A Phase II Study of Daratumumab in Patients with High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma: First Report of Efficacy and Safety. Blood, 2019, 134, 1898-1898.	1.4	6
77	In Search of Missed Tumors: Next-Generation Sequencing for Minimal Residual Disease Detection in Multiple Myeloma Comes of Age. , 2019, 16, .		0
78	IgL Translocations for Risk Stratification in Multiple Myeloma. , 2019, 16, .		0
79	The Microbiome: A New Variable in Multiple Myeloma Disease Progression. , 2019, 16, .		0
80	Repositioning the Repurposed Drug, a Structural Study of Thalidomide Analogs. , 2019, 16, .		1
81	RewIRE(1Î±)ing the Unfolded Protein Response in Multiple Myeloma. , 2019, 16, .		0
82	XBP1s: Getting to the Roots of Multiple Myeloma. , 2019, 16, .		0
83	Multiple Myeloma Pathogenesis: The Role of Junb in Bone Marrow Angiogenesis. Blood, 2019, 134, 4341-4341.	1.4	0
84	The Transmembrane Receptor Roundabout 1 (ROBO1) Is Necessary for Multiple Myeloma Proliferation and Homing to the Bone Marrow Niche. Blood, 2019, 134, 507-507.	1.4	0
85	MYC Overexpressing Multiple Myeloma Are Dependent on GLS1. Blood, 2019, 134, 853-853.	1.4	0
86	Immunotherapy for hematological malignancies. Journal of Life Sciences (Westlake Village, Calif), 2019, 1, 46-52.	1.8	5
87	Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab. Molecular Cancer Therapeutics, 2018, 17, 1454-1463.	4.1	70
88	Platelets Enhance Multiple Myeloma Progression via IL-1Î² Upregulation. Clinical Cancer Research, 2018, 24, 2430-2439.	7.0	44
89	The bone-marrow niche in MDS and MGUS: implications for AML and MM. Nature Reviews Clinical Oncology, 2018, 15, 219-233.	27.6	120
90	Current use of monoclonal antibodies in the treatment of multiple myeloma. British Journal of Haematology, 2018, 181, 447-459.	2.5	37

#	Article	IF	Citations
91	Profiling of circulating exosomal miRNAs in patients with WaldenstrÃ¶m Macroglobulinemia. PLoS ONE, 2018, 13, e0204589.	2.5	17
92	Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients. Blood, 2018, 132, 2608-2612.	1.4	29
93	Triply Loaded Nitroxide Brush-Arm Star Polymers Enable Metal-Free Millimetric Tumor Detection by Magnetic Resonance Imaging. ACS Nano, 2018, 12, 11343-11354.	14.6	56
94	Safety and immunogenicity of conjugate quadrivalent meningococcal vaccination after hematopoietic cell transplantation. Blood Advances, 2018, 2, 1272-1276.	5.2	9
95	A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplantâ€ineligible multiple myeloma. British Journal of Haematology, 2018, 182, 222-230.	2.5	118
96	Inhibition of microRNA-138 enhances bone formation in multiple myeloma bone marrow niche. Leukemia, 2018, 32, 1739-1750.	7.2	34
97	Blocking IFNAR1 inhibits multiple myelomaâ€“driven Treg expansion and immunosuppression. Journal of Clinical Investigation, 2018, 128, 2487-2499.	8.2	80
98	Aspirin Use and Survival in Multiple Myeloma Patients. Blood, 2018, 132, 3250-3250.	1.4	2
99	The Role of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Multiple Myeloma: Immunomodulator Maintenance Post Autologous Stem Cell Transplant (ASCT) Predicts Better Outcome. Blood, 2018, 132, 749-749.	1.4	6
100	Single-Cell RNA Sequencing Reveals Compromised Immune Microenvironment in Precursor Stages of Multiple Myeloma. Blood, 2018, 132, 2603-2603.	1.4	1
101	Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma. Blood, 2018, 132, 804-804.	1.4	42
102	Immunotherapy in Multiple Myeloma: The Era of CAR T Cell Therapy. , 2018, 15, .		0
103	Redefining Risks in Multiple Myeloma is Still a Work in Progress. , 2018, 15, .		0
104	When Does Monoclonal Gammopathy Acquire Significance?. , 2018, 15, .		0
105	Targeting a Myeloma Translocation for the First Time: The t(11;14) Journey. , 2018, 15, .		1
106	Can We Vaccinate Our Way Out of Multiple Myeloma Progression?. , 2018, 15, .		0
107	New Approaches to Multiple Myeloma. European Oncology and Haematology, 2018, 14, 18.	0.0	0
108	A Phase Ib/II Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib Plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma. Blood, 2018, 132, 3263-3263.	1.4	1

#	Article	IF	Citations
109	Evaluation of Re-Intensification of Daratumumab to Weekly or Biweekly Dosing Schedule. Blood, 2018, 132, 2024-2024.	1.4	0
110	Deciphering Clonal Evolution and Dissemination of Multiple Myeloma Cells In Vivo. Blood, 2018, 132, 55-55.	1.4	0
111	Evolving Areas of Consensus and Disagreement Among Experts in Treatment of Patients with Multiple Myeloma (MM). Blood, 2018, 132, 5664-5664.	1.4	0
112	A Phase II Study of the Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone (RVD) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma: Promising Activity and Manageable Toxicity, Including in High Risk Disease. Blood, 2018, 132, 1981-1981.	1.4	1
113	In Vivo Modeling of Clonal Competition Using CRISPR-Based Gene Editing Reveals Novel Fitness Variables in Multiple Myeloma. Blood, 2018, 132, 57-57.	1.4	0
114	Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma. American Journal of Hematology, 2017, 92, 448-453.	4.1	26
115	Prognostic role of circulating exosomal miRNAs in multiple myeloma. Blood, 2017, 129, 2429-2436.	1.4	214
116	Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein <scp>MUC</scp>1. British Journal of Haematology, 2017, 176, 929-938.	2.5	34
117	Serum IgM level as predictor of symptomatic hyperviscosity in patients with WaldenstrÃ¶m macroglobulinaemia. British Journal of Haematology, 2017, 177, 717-725.	2.5	58
118	A novel in vivo model for studying conditional dual loss of BLIMPâ€1 and p53 in Bâ€cells, leading to tumor transformation. American Journal of Hematology, 2017, 92, E138-E145.	4.1	3
119	Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma. Science Translational Medicine, 2017, 9, .	12.4	53
120	The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma. Cell Reports, 2017, 19, 218-224.	6.4	92
121	IgM myeloma: A multicenter retrospective study of 134 patients. American Journal of Hematology, 2017, 92, 746-751.	4.1	45
122	Bone Marrow Stroma and Vascular Contributions to Myeloma Bone Homing. Current Osteoporosis Reports, 2017, 15, 499-506.	3.6	23
123	Genomic complexity of multiple myeloma and its clinical implications. Nature Reviews Clinical Oncology, 2017, 14, 100-113.	27.6	413
124	Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214). Clinical Cancer Research, 2017, 23, 2400-2404.	7.0	23
125	Multiple Myeloma and the immune microenvironment. Current Cancer Drug Targets, 2017, 17, 1-1.	1.6	59
126	Established and Novel Prognostic Biomarkers in Multiple Myeloma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 548-560.	3.8	21

#	Article	IF	Citations
127	Human regulatory T cells undergo self-inflicted damage via granzyme pathways upon activation. JCI Insight, 2017, 2, .	5.0	31
128	The importance of the genomic landscape in WaldenstrÃ¶m's Macroglobulinemia for targeted therapeutical interventions. Oncotarget, 2017, 8, 35435-35444.	1.8	4
129	Future Directions in the Evaluation and Treatment of Precursor Plasma Cell Disorders. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e400-e406.	3.8	2
130	Central nervous system involvement by WaldenstrÃ¶m macroglobulinaemia (Bingâ€Neel syndrome): a multiâ€institutional retrospective study. British Journal of Haematology, 2016, 172, 709-715.	2.5	87
131	<scp>TAK</scp>â€228 (formerly <scp>MLN</scp>0128), an investigational oral dual <scp>TORC</scp>1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, nonâ€Hodgkin lymphoma, or WaldenstrÃ¶m's macroglobulinemia. American Journal of Hematology, 2016, 91, 400-405.	4.1	89
132	Brief treatment with a highly selective immunoproteasome inhibitor promotes long-term cardiac allograft acceptance in mice. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E8425-E8432.	7.1	54
133	Exome sequencing reveals recurrent germ line variants in patients with familial WaldenstrÃ¶m macroglobulinemia. Blood, 2016, 127, 2598-2606.	1.4	22
134	Epigenomics in Waldenstrom's macroglobulinaemia. Best Practice and Research in Clinical Haematology, 2016, 29, 156-160.	1.7	1
135	Epigenetics in Multiple Myeloma. Cancer Treatment and Research, 2016, 169, 35-49.	0.5	7
136	Genomic Aberrations in Multiple Myeloma. Cancer Treatment and Research, 2016, 169, 23-34.	0.5	21
137	Response to ibrutinib in a patient with IgG lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation. Leukemia and Lymphoma, 2016, 57, 2699-2701.	1.3	4
138	Targeting SDF-1 in multiple myeloma tumor microenvironment. Cancer Letters, 2016, 380, 315-318.	7.2	31
139	Cancer Cell Dissemination and Homing to the Bone Marrow in a Zebrafish Model. Cancer Research, 2016, 76, 463-471.	0.9	39
140	Exosomes in Tumor Angiogenesis. Methods in Molecular Biology, 2016, 1464, 25-34.	0.9	32
141	In Vivo Genome-Wide Crispr Library Screen in a Xenograft Mouse Model of Tumor Growth and Metastasis of Multiple Myeloma. Blood, 2016, 128, 1137-1137.	1.4	2
142	Whole-Exome Sequencing and Targeted Deep Sequencing of cfDNA Enables a Comprehensive Mutational Profiling of Multiple Myeloma. Blood, 2016, 128, 197-197.	1.4	8
143	Prospective, Multicenter Clinical Trial of Everolimus As Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214). Blood, 2016, 128, 4487-4487.	1.4	2
144	Whole Exome Sequencing and Targeted Sequencing Reveal the Heterogeneity of Genomic Evolution and Mutational Profile in Smoldering Multiple Myeloma. Blood, 2016, 128, 237-237.	1.4	0

#	Article	IF	Citations
145	Dual Conditional Loss of BLIMP-1 and p53 in B-Cells Drives B-Cell Lymphomagenesis. Blood, 2016, 128, 4169-4169.	1.4	0
146	In Vivo Analysis of Clonal Evolution of Multiple Myeloma. Blood, 2016, 128, 799-799.	1.4	0
147	Profiling of Circulating Exosomes in Patients with WaldenstrÃ¶m Macroglobulinemia. Blood, 2016, 128, 2940-2940.	1.4	1
148	Clinical perspective: Linking psychosocial care to the disease continuum in patients with multiple myeloma. Palliative and Supportive Care, 2015, 13, 829-838.	1.0	6
149	Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. British Journal of Haematology, 2015, 169, 851-858.	2.5	63
150	CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation. Cell Reports, 2015, 12, 622-635.	6.4	123
151	Hypoxia Promotes Dissemination and Colonization in New Bone Marrow Niches in WaldenstrÃ¶m Macroglobulinemia. Molecular Cancer Research, 2015, 13, 263-272.	3.4	23
152	Cyclophosphamide, bortezomib, and dexamethasone combination in waldenstrom macroglobulinemia. American Journal of Hematology, 2015, 90, E122-3.	4.1	13
153	The cancer glycome: Carbohydrates as mediators of metastasis. Blood Reviews, 2015, 29, 269-279.	5.7	91
154	Dynamic interplay between bone and multiple myeloma: Emerging roles of the osteoblast. Bone, 2015, 75, 161-169.	2.9	55
155	Ibrutinib in Previously Treated WaldenstrÃ¶mâ€™s Macroglobulinemia. New England Journal of Medicine, 2015, 372, 1430-1440.	27.0	810
156	Aberrant Levels of miRNAs in Bone Marrow Microenvironment and Peripheral Blood of Myeloma Patients and Disease Progression. Journal of Molecular Diagnostics, 2015, 17, 669-678.	2.8	36
157	Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomideâ€“bortezomib combinations. British Journal of Haematology, 2015, 169, 843-850.	2.5	66
158	Drug-Related Pneumonitis During Mammalian Target of Rapamycin Inhibitor Therapy: Radiographic Pattern-Based Approach in WaldenstrÃ¶m Macroglobulinemia as a Paradigm. Oncologist, 2015, 20, 1077-1083.	3.7	46
159	Anti-Sclerostin Treatment Prevents Multiple Myeloma Induced Bone Loss and Reduces Tumor Burden. Blood, 2015, 126, 119-119.	1.4	14
160	Long-Term Outcome of a Prospective Study of Bortezomib, Dexamethasone and Rituximab (BDR) in Previously Untreated, Symptomatic Patients with Waldenstrom's Macroglobulinemia. Blood, 2015, 126, 1833-1833.	1.4	23
161	Mutational Profile and Prognostic Relevance of Circulating Tumor Cells in Multiple Myeloma. Blood, 2015, 126, 23-23.	1.4	37
162	A Phase II Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVD-lite) for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma. Blood, 2015, 126, 4217-4217.	1.4	8

#	Article	IF	Citations
163	Final Results of the Phase I/II Study of Chemosensitization Using the CXCR4 Inhibitor Plerixafor in Combination with Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma. Blood, 2015, 126, 4256-4256.	1.4	4
164	Characterization of the Role of Regulatory T Cells (Tregs) in Inducing Progression of Multiple Myeloma. Blood, 2015, 126, 502-502.	1.4	4
165	MYC Regulation Via the LIN28B/Let-7 Axis in Multiple Myeloma. Blood, 2015, 126, 1755-1755.	1.4	0
166	A New Model for Studying the Dissemination of Myeloma Cells throughout the Bone Marrow Using Embryonic Zebrafish. Blood, 2015, 126, 915-915.	1.4	0
167	Circulating Exosomal microRNAs Are Prognostic Markers in Multiple Myeloma. Blood, 2015, 126, 1770-1770.	1.4	4
168	Platelets/Megakaryocytes Are Critical Regulators of Tumor Progression in Multiple Myeloma. Blood, 2015, 126, 1793-1793.	1.4	1
169	Global Epigenetic Regulation of MicroRNAs in Multiple Myeloma. PLoS ONE, 2014, 9, e110973.	2.5	29
170	How I treat smoldering multiple myeloma. Blood, 2014, 124, 3380-3388.	1.4	41
171	SDF-1 Inhibition Targets the Bone Marrow Niche for Cancer Therapy. Cell Reports, 2014, 9, 118-128.	6.4	116
172	Team Work Matters: Dual Inhibition Puts Non-Hodgkin Lymphoma Under Siege. Clinical Cancer Research, 2014, 20, 5863-5865.	7.0	1
173	Biomarkers of Bone Remodeling in Multiple Myeloma Patients to Tailor Bisphosphonate Therapy. Clinical Cancer Research, 2014, 20, 3955-3961.	7.0	33
174	Investigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche model. Blood, 2014, 124, 3250-3259.	1.4	109
175	Role of endothelial progenitor cells in cancer progression. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 26-39.	7.4	70
176	Regulation of microRNAs in cancer metastasis. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1845, 255-265.	7.4	132
177	Altered cytokine and chemokine profiles in multiple myeloma and its precursor disease. Cytokine, 2014, 69, 294-297.	3.2	15
178	Engineered nanomedicine for myeloma and bone microenvironment targeting. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 10287-10292.	7.1	234
179	CXCR7-dependent angiogenic mononuclear cell trafficking regulates tumor progression in multiple myeloma. Blood, 2014, 124, 1905-1914.	1.4	32
180	The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma. Blood, 2014, 124, 1765-1776.	1.4	97

#	Article	IF	Citations
181	Pyk2 promotes tumor progression in multiple myeloma. Blood, 2014, 124, 2675-2686.	1.4	51
182	C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma. Blood, 2014, 123, 4120-4131.	1.4	187
183	Treatment recommendations for patients with WaldenstrÃ¶m macroglobulinemia (WM) and related disorders: IWWM-7 consensus. Blood, 2014, 124, 1404-1411.	1.4	138
184	Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating WaldenstrÃ¶m's macroglobulinemia. Blood, 2014, 124, 503-510.	1.4	168
185	Final Results of Phase I/II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Combination with Bortezomib and Rituximab (RVR) in Relapsed or Refractory Waldenstrom Macroglobulinemia. Blood, 2014, 124, 3081-3081.	1.4	16
186	Clonal-Heterogeneity and Propensity for Bone Metastasis in Multiple Myeloma. Blood, 2014, 124, 3370-3370.	1.4	1
187	Clinical Profile of Single-Agent Oprozomib in Patients (Pts) with Multiple Myeloma (MM): Updated Results from a Multicenter, Open-Label, Dose Escalation Phase 1b/2 Study. Blood, 2014, 124, 34-34.	1.4	21
188	Dissecting the Mechanisms of Activity of SLAMF7 and the Targeting Antibody Elotuzumab in Multiple Myeloma. Blood, 2014, 124, 3431-3431.	1.4	8
189	Phase Ib Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma. Blood, 2014, 124, 3483-3483.	1.4	14
190	Biological and Clinical Implications of Clonal Heterogeneity and Clonal Evolution in Multiple Myeloma. Current Cancer Therapy Reviews, 2014, 10, 70-79.	0.3	34
191	Exosomes in Hematologic Malignancies. , 2014, 11, .		0
192	Proteomic Characterization of the Multiple Myeloma Bone Marrow Extracellular Matrix. Blood, 2014, 124, 2051-2051.	1.4	1
193	Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma. Blood, 2014, 124, 5777-5777.	1.4	2
194	Molecular Modification of the Microenvironment by the Tumor Clone. Blood, 2014, 124, SCI-49-SCI-49.	1.4	1
195	Citron Rho-Interacting Serine/Threonine kinase (CIT) Is a Novel Therapeutic Target in Multiple Myeloma Cells. Blood, 2014, 124, 3430-3430.	1.4	0
196	Proline-Rich Tyrosine Kinase (Pyk2) Promotes Tumor Progression in Multiple Myeloma (MM) and Represents a Novel Target for Therapy in MM. Blood, 2014, 124, 2101-2101.	1.4	0
197	Prognostic Value of Circulating Exosomal microRNAs in 112 Patients with Multiple Myeloma. Blood, 2014, 124, 2056-2056.	1.4	0
198	Response assessment in <scp>W</scp>aldenstrÃ¶m macroglobulinaemia: update from the <scp>VI</scp>th <scp>I</scp>nternational <scp>W</scp>orkshop. British Journal of Haematology, 2013, 160, 171-176.	2.5	226

#	Article	IF	Citations
199	Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory WaldenstrÃ¶m macroglobulinemia. Blood, 2013, 121, 1296-1303.	1.4	46
200	Phase I/II Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy In Relapsed Or Relapsed/Refractory Multiple Myeloma. Blood, 2013, 122, 1947-1947.	1.4	4
201	A Prospective Multicenter Study Of The Brutonâ€™s Tyrosine Kinase Inhibitor Ibrutinib In Patients With Relapsed Or Refractory Waldenstromâ€™s Macroglobulinemia. Blood, 2013, 122, 251-251.	1.4	34
202	A Novel Activating Mutation Of CXCR4 Plays a Crucial Role In Waldenstrom Macroglobulinemia Biology. Blood, 2013, 122, 272-272.	1.4	10
203	Phase I/II Trial Of Everolimus, Bortezomib and Rituximab In Relapsed Or Relapsed/Refractory Waldenstrom's Macroglobulinemia. Blood, 2013, 122, 4402-4402.	1.4	5
204	Clinical Characteristics and Treatment Outcome Of CNS Involvement (Bing-Neel Syndrome) In Waldenstromâ€™s Macroglobulinemia. Blood, 2013, 122, 5090-5090.	1.4	18
205	Bone Marrow Mobilization Of Endothelial Progenitor Cells Represents An Early Pathogenic Event During Multiple Myeloma Progression. Blood, 2013, 122, 680-680.	1.4	4
206	Carfilzomib, Rituximab and Dexamethasone (CaRD) Is Highly Active and Offers a Neuropathy Sparing Approach For Proteasome-Inhibitor Based Therapy In Waldenstromâ€™s Macroglobulinemia. Blood, 2013, 122, 757-757.	1.4	6
207	Proline-Rich Tyrosine Kinase (Pyk2) Promotes Tumor Progression In Multiple Myeloma Through Modulation Of Wnt/Î²-Catenin Signaling Pathway. Blood, 2013, 122, 3094-3094.	1.4	0
208	Metabolomic Profiling Identifies Mechanisms Regulating Hypoxia-Induced Drug Resistance In Multiple Myeloma. Blood, 2013, 122, 121-121.	1.4	0
209	Mirna Expression Profiling and Proteomic Analysis Of Circulating Exosomes From Multiple Myeloma Patients. Blood, 2013, 122, 3086-3086.	1.4	2
210	Class I PI3K Isoforms Exert a Differential Role On Survival and Cell Trafficking In Multiple Myeloma. Blood, 2013, 122, 3159-3159.	1.4	0
211	Extramedullary Disease In Waldenstromâ€™s Macroglobulinemia. Blood, 2013, 122, 1773-1773.	1.4	0
212	A Case-Control Epidemiological Study Of Waldenstrom Macroglobulinemia. Blood, 2013, 122, 1713-1713.	1.4	0
213	Hypoxia Induces Drug Resistance In Multiple Myeloma. Blood, 2013, 122, 1852-1852.	1.4	2
214	Methylation-Dependent Epigenetic Silencing Of Mir-152 and Mir-10b-5p Plays a Crucial Role In Modulating Tumor Progression In Multiple Myeloma. Blood, 2013, 122, 3751-3751.	1.4	0
215	Microrna-Dependent Modulation Of Osteogenesis In a 3D In Vitro Bone Marrow Model System Of Multiple Myeloma. Blood, 2013, 122, 3093-3093.	1.4	0
216	Myeloma as a model for the process of metastasis: implications for therapy. Blood, 2012, 120, 20-30.	1.4	163

#	Article	IF	Citations
217	Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. Blood, 2012, 119, 5782-5794.	1.4	268
218	Multiple Myeloma Mesenchymal Stem Cells: Characterization, Origin, and Tumor-Promoting Effects. Clinical Cancer Research, 2012, 18, 342-349.	7.0	118
219	Are you sure this is Waldenstrom macroglobulinemia?. Hematology American Society of Hematology Education Program, 2012, 2012, 586-94.	2.5	21
220	Are you sure this is WaldenstrÃ¶m macroglobulinemia?. Hematology American Society of Hematology Education Program, 2012, 2012, 586-594.	2.5	28
221	In Vivo Targeting of Stromal-Derived Factor-1 As a Strategy to Prevent Myeloma Cell Dissemination to Distant Bone Marrow Niches. Blood, 2012, 120, 440-440.	1.4	4
222	Multiple Myeloma-Derived Bone-Marrow Mesenchymal Stem Cells: Microrna-, Gene Expression-Profiling and Functional Characterization. Blood, 2012, 120, 1837-1837.	1.4	0
223	CRM1 Inhibition Abrogates Osteoclast Formation and Bone Resorption Via Inhibition of RANKL-Induced NFÎºB While Sparing Osteoblastogenesis: Further Therapeutic Implication in Multiple Myeloma. Blood, 2012, 120, 1835-1835.	1.4	1
224	Metabolomic Profiling Identifies Mechanisms Regulating Hypoxia-Induced Drug Resistance in Multiple Myeloma. Blood, 2012, 120, 3944-3944.	1.4	0
225	Let-7 Microrna Family Members Regulate Cell Proliferation in Multiple Myeloma. Blood, 2012, 120, 570-570.	1.4	0
226	Targeting the Bone Marrow in Waldenstrom Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, S65-S69.	0.4	6
227	Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study. Lancet Oncology, The, 2011, 12, 263-272.	10.7	88
228	The New CXCR4 Inhibitor MDX-1338 Exerts Anti-Tumor Activity in Multiple Myeloma. Blood, 2011, 118, 1844-1844.	1.4	2
229	Phase I Trial of Plerixafor and Bortezomib As a Chemosensitization Strategy in Relapsed or Relapsed/Refractory Multiple Myeloma. Blood, 2011, 118, 1874-1874.	1.4	1
230	Phase I Trial of Everolimus and Rituximab or Everolimus, Bortezomib and Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia. Blood, 2011, 118, 2705-2705.	1.4	1
231	Final Results of the Phase II Trial of Single Agent Panobinostat (LBH589) in Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia. Blood, 2011, 118, 2706-2706.	1.4	1
232	Prospective, Multicenter Study of the MTOR Inhibitor Everolimus (RAD001) As Primary Therapy in Waldenstrom's Macroglobulinemia. Blood, 2011, 118, 2951-2951.	1.4	17
233	Incidence of Peripheral Neuropathy in Waldenstroì^m Macroglobulinemia Patients At Diagnosis,. Blood, 2011, 118, 3692-3692.	1.4	3
234	Biomarker Correlation with Outcomes in Patients with Relapsed or Refractory Multiple Myeloma on a Phase I Study of Everolimus in Combination with Lenalidomide,. Blood, 2011, 118, 3966-3966.	1.4	2

#	Article	IF	Citations
235	Stroma-Derived Exosomes Mediate Oncogenesis in Multiple Myeloma. Blood, 2011, 118, 625-625.	1.4	2
236	Similar Dreams, Different Journeys. , 2011, 8, .		0
237	Hypoxia Promotes Dissemination of Multiple Myeloma Through Acquisition of Endothelial to Mesenchymal Transition (EMT) Features. Blood, 2011, 118, 471-471.	1.4	0
238	Inhibition of c-Myc Expression and Function in Hematologic Malignancies. Blood, 2011, 118, 1409-1409.	1.4	0
239	Perifosine Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Final Results of a Phase I/II Trial. Blood, 2011, 118, 815-815.	1.4	0
240	The Role of PI3K Signaling in Cell Trafficking of Multiple Myeloma. Blood, 2011, 118, 1804-1804.	1.4	0
241	RVD Induction Followed by Consolidation with ASCT in Patients with Newly Diagnosed Multiple Myeloma,. Blood, 2011, 118, 4134-4134.	1.4	0
242	L-Stereoisomer RNA Oligonucleotide Anti-SDF-1 (Nox-A12) Disrupts the Interaction of Multiple Myeloma Cells with the Bone Marrow Milieu In Vivo, Leading to Enhanced Sensitivity to Bortezomib. Blood, 2011, 118, 887-887.	1.4	0
243	Role of TORC1 and TORC2 in Multiple Myeloma. Blood, 2011, 118, 1815-1815.	1.4	1
244	The Role of Bortezomib-Containing Regimens in Improving Response in Patients with Waldenstrom Macroglobulinemia. Blood, 2011, 118, 2713-2713.	1.4	0
245	MicroRNA-155 As a Potential Plasma Biomarker for Chronic Lymphocytic Leukemia and Waldenstrom Macroglobulinemia,. Blood, 2011, 118, 3669-3669.	1.4	0
246	Dissecting the role of CXCR7 in Cell Trafficking of Endothelial-Cells and Endothelial-Progenitor-Cells in Multiple Myeloma,. Blood, 2011, 118, 3934-3934.	1.4	0
247	LNA Anti-MicroRNA-155: A Novel Therapeutic Strategy in Waldenstrom Macroglobulinemia and Chronic Lymphocytic Leukemia. Blood, 2011, 118, 2728-2728.	1.4	0
248	Deregulation of TNFRSF18 (GITR) Through Promoter CpG Island Methylation Induces Tumor Proliferation in Multiple Myeloma. Blood, 2011, 118, 2424-2424.	1.4	0
249	Eph-B2/Ephrin-B2 Interaction Plays a Major Role In the Adhesion and Survival of WM Cells In the Context of the Bone Marrow Microenvironment. Blood, 2010, 116, 142-142.	1.4	2
250	Phase I Trial of Plerixafor and Bortezomib as a Chemosensitization Strategy In Relapsed or Relapsed/Refractory Multiple Myeloma. Blood, 2010, 116, 1943-1943.	1.4	2
251	Updated Results of a Phase I Study of RAD001 In Combination with Lenalidomide In Patients with Relapsed or Refractory Multiple Myeloma with Pharmacodynamic and Pharmacokinetic Analysis. Blood, 2010, 116, 3051-3051.	1.4	4
252	The Role of Serum Immunoglobulin Free Light Chain In Response and Progression In Waldenstrom Macroglobulinemia. Blood, 2010, 116, 3095-3095.	1.4	2

#	Article	IF	Citations
253	Phase II Trial of Single Agent Panobinostat (LBH589) In Relapsed or Relapsed/Refractory Waldenstrom Macroglobulinemia. Blood, 2010, 116, 3952-3952.	1.4	9
254	Selectin Inhibition Disrupts Multiple Myeloma Cells Interaction with the Bone Marrow Microenvironment and Sensitizes Them to Therapy. Blood, 2010, 116, 453-453.	1.4	1
255	Final Results of the Phase I/II Trial of Weekly Bortezomib In Combination with Temsirolimus (CCI-779) In Relapsed or Relapsed/Refractory Multiple Myeloma Specifically In Patients Refractory to Bortezomib. Blood, 2010, 116, 990-990.	1.4	5
256	Genome Wide DNA Methylation Profiling In Patients with Multiple Myeloma.. Blood, 2010, 116, 3622-3622.	1.4	12
257	Dynamic Regulation of the Level of Hypoxia In the Bone Marrow Regulates Cell Dissemination In Multiple Myeloma. Blood, 2010, 116, 4035-4035.	1.4	0
258	Human Monoclonal Antibody Targeting IL-17A (AIN457) Down-Regulates MM Cell-Growth and Survival and Inhibits Osteoclast Development In Vitro and In Vivo: A Potential Novel Therapeutic Application In Myeloma. Blood, 2010, 116, 456-456.	1.4	7
259	Proteomic Studies Identify Citron Rho Interacting Kinase (CRIK), a Novel Protein That Regulates Proliferation and Survival In Multiple Myeloma Cells. Blood, 2010, 116, 2958-2958.	1.4	0
260	HevyliteÂ®, a New Marker of Tumor Measurement In Waldenstrom Macroglobulinemia. Blood, 2010, 116, 5076-5076.	1.4	3
261	LNA Anti-Microrna-155: a Novel Therapeutic Strategy In Waldenstrom Macroglobulinemia and Chronic Lymphocytic Leukemia. Blood, 2010, 116, 4914-4914.	1.4	0
262	Promoter-Wide Transcriptional Deregulation In Waldenstrom Macroglobulinemia. Blood, 2010, 116, 3620-3620.	1.4	0
263	The Role of PET Scan Imaging In Waldenstrom Macroglobulinemia. Blood, 2010, 116, 4153-4153.	1.4	0
264	Finding the right academic job. Hematology American Society of Hematology Education Program, 2009, 2009, 729-733.	2.5	5
265	Novel Therapeutic Agents in WaldenstrÃ¶m's Macroglobulinemia. Clinical Lymphoma and Myeloma, 2009, 9, 84-86.	1.4	4
266	ASH evidence-based guidelines: what is the role of maintenance therapy in the treatment of multiple myeloma?. Hematology American Society of Hematology Education Program, 2009, 2009, 587-589.	2.5	11
267	CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood, 2009, 113, 4341-4351.	1.4	398
268	MicroRNA Changes Occur in Multiple Myeloma Cells in the Context of Bone Marrow Milieu.. Blood, 2009, 114, 1785-1785.	1.4	1
269	Lack of Response to Vaccination in MGUS and Stable Myeloma.. Blood, 2009, 114, 1852-1852.	1.4	11
270	RAD001 Exerts Anti-Tumor Activity in Waldenstrom Macroglobulinemia.. Blood, 2009, 114, 3732-3732.	1.4	2

#	Article	IF	Citations
271	Role of Selectins in the Pathogenesis of Multiple Myeloma.. Blood, 2009, 114, 951-951.	1.4	1
272	Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia.. Blood, 2009, 114, 2727-2727.	1.4	0
273	Primary Waldesntrom Macroglobulinemia Cells Harbor Constitutive Activation of Akt, mTOR, Rictor and Raptor: Rational for Testing a Dual Inhibitor of the PI3K/Akt and mTOR Pathways in This Disease.. Blood, 2009, 114, 3843-3843.	1.4	0
274	Serum Immunoglobulin Free Light Chain (sFLC) Measurement as a New Marker of Response to Therapy and Survival in Waldenstrom Macroglobulinemia (WM).. Blood, 2009, 114, 3952-3952.	1.4	0
275	Citron Rho Interacting Kinase (CRIK) Regulates Survival in IL-6 Dependent Multiple Myeloma Cells.. Blood, 2009, 114, 1825-1825.	1.4	0
276	Eph-B2 Receptor Tyrosine Kinase Is Overexpressed in Waldenstrom's Macroglubulinemia and Plays a Major Role in Its Interaction with the Bone Marrow Microenvironment.. Blood, 2009, 114, 2935-2935.	1.4	0
277	The Role of FGFR in the Progression of Waldenstrom's Macroglubulinemia and the Effect of Its Inhibition by TKI-258.. Blood, 2009, 114, 3737-3737.	1.4	0
278	The Effect of the CXCR4 Inhibitors, AMD3100 and AMD3465, in Multiple Myeloma Cell Homing and Its Interaction with the Bone Marrow Microenvironment.. Blood, 2009, 114, 1826-1826.	1.4	0
279	Selective Inhibition of the Chymotrypsin-Like Activity of the Immunoproteasome and Constitutive Proteasome Represents a Valid Anti-Tumor Strategy in Waldenstrom Macroglobulinemia.. Blood, 2009, 114, 4911-4911.	1.4	3
280	Carfilzomib Exerts Anti-Neoplastic Activity in Waldenstrom Macroglobulinemia.. Blood, 2009, 114, 4916-4916.	1.4	1
281	Role of Hypoxia in the Progression and Dissemination of Multiple Myeloma.. Blood, 2009, 114, 421-421.	1.4	0
282	Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Untreated Patients with Waldenstrom's Macroglobulinemia.. Blood, 2009, 114, 3752-3752.	1.4	2
283	PET/CT a New Marker of Response in Waldenstrom Macroglobulinemia (WM).. Blood, 2009, 114, 1937-1937.	1.4	2
284	Phase II Trial of Weekly Bortezomib in Combination with CCI-779 (temsirolimus) in Relapsed or Relapsed/Refractory Multiple Myeloma.. Blood, 2009, 114, 748-748.	1.4	0
285	Phase II Trial of the mTOR Inhibitor RAD001 in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: The Dana Farber Cancer Institute Experience.. Blood, 2008, 112, 1011-1011.	1.4	1
286	Phase I Trial of CCI-779 (Temsirolimus) and Weekly Bortezomib in Relapsed and/or Refractory Multiple Myeloma. Blood, 2008, 112, 3696-3696.	1.4	26
287	Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia. Blood, 2008, 112, 832-832.	1.4	7
288	Identification of An Atypical Paraprotein with Inconsistent M-Spike Quantitation in Four Patients with Waldenstromâ€™s Macroglobulinemia. Blood, 2008, 112, 5145-5145.	1.4	0

#	Article	IF	Citations
289	The Effect of Insulin-Like Growth Factor 1 on Waldenstrom Macroglobulinemia. Blood, 2008, 112, 4994-4994.	1.4	0
290	TH17 Pathway Promotes Tumor Cell Growth and Suppresses Immune Function in Myeloma: Potential for Therapeutic Application. Blood, 2008, 112, 2737-2737.	1.4	0
291	Emerging drugs in multiple myeloma. Expert Opinion on Emerging Drugs, 2007, 12, 155-163.	2.4	11
292	Serum Immunoglobulin Free Light Chain (sFLC) Is a Sensitive Marker of Response in Waldenstrom Macroglobulinemia (WM).. Blood, 2007, 110, 1486-1486.	1.4	1
293	The Combination of Bortezomib and NPI-0052 Exerts Anti-Tumor Activity in Waldenstrom Macroglobulinemia (WM).. Blood, 2007, 110, 1516-1516.	1.4	19
294	In Vivo Mobilization of Multiple Myeloma Cells Out of the Bone Marrow Using the CXCR4 Inhibitor AMD3100 and Bortezomib: Implications for Sensitization of Myeloma Cells to Apoptosis.. Blood, 2007, 110, 2501-2501.	1.4	16
295	Phase II Trial of Perifosine (KRX-0401) in Relapsed and/or Refractory Waldenstrol̂m Macroglobulinemia: Preliminary Results.. Blood, 2007, 110, 4493-4493.	1.4	1
296	Phase II Trial of the Oral mTOR Inhibitor RAD001 (Everolimus) in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.. Blood, 2007, 110, 4496-4496.	1.4	2
297	Targeting NF-kB by Perifosine, Bortezomib and Rituximab in Waldenstrom Macroglobulinemia (WM).. Blood, 2007, 110, 2512-2512.	1.4	0
298	Phase II Trial of Combination of Bortezomib and Rituximab in Relapsed and/or Refractory Waldenstrom Macroglobulinemia: Preliminary Results.. Blood, 2007, 110, 4494-4494.	1.4	1
299	The Interaction of CXCR4/SDF-1 and VLA-4 Regulates Adhesion and Transendothelial Migration in Waldenstrom Macroglobulinemia.. Blood, 2007, 110, 2617-2617.	1.4	0
300	Resveratrol Exerts Antiproliferative Effect and Induces Apoptosis in Waldenstromâ€™s Macroglobulinemia.. Blood, 2007, 110, 1383-1383.	1.4	2
301	Regulation of the New CXCR7 Receptor in Plasma Cell Dyscrasias.. Blood, 2007, 110, 3527-3527.	1.4	0
302	Serum Free Light Chain in Waldenstrom Macroglobulinemia.. Blood, 2006, 108, 2420-2420.	1.4	11
303	The Selective Protein Kinase CB Inhibitor, Enzastaurin, Induces In Vitro and In Vivo Antitumor Activity in Waldenstromâ€™s Macroglobulinemia.. Blood, 2006, 108, 2496-2496.	1.4	2
304	Novel Agent Perifosine Enhances Antitumor Activity of Bortezomib, Rituximab and Other Conventional Therapies in Waldenstromâ€™s Macroglobulinemia.. Blood, 2006, 108, 2517-2517.	1.4	3
305	Bortezomib, Dexamethasone and Rituximab (BDR) Is a Highly Active Regimen in the Primary Therapy of Waldenstromâ€™s Macroglobulinemia: Planned Interim Results of WMCTG Clinical Trial 05-180.. Blood, 2006, 108, 2765-2765.	1.4	10
306	Inhibition of ERK1/2 Activity by the MEK1/2 Inhibitor AZD6244 (ARRY-142886) Induces Human Multiple Myeloma Cell Apoptosis in the Bone Marrow Microenvironment: A New Therapeutic Strategy for MM.. Blood, 2006, 108, 3460-3460.	1.4	1

#	Article	IF	Citations
307	Molecular Mechanisms Regulating Resistance to the Akt Inhibitor Perifosine in Waldenstromâ€™s Macroglobulinemia, the Role of the ERK and PKC Pathways.. Blood, 2006, 108, 2416-2416.	1.4	1
308	Imatinib Mesylate (GleevecÂ®) Is Active in Relapsed/Refractory Waldenstromâ€™s Macroglobulinemia: Planned Interim Results of WMCTG Clinical Trial 05-140.. Blood, 2006, 108, 2484-2484.	1.4	2
309	The CXCR4/SDF-1 Axis Regulates Migration and Adhesion in Waldenstrom Macroglobulinemia.. Blood, 2006, 108, 2418-2418.	1.4	2
310	A Novel Real-Time In Vivo Homing Model of Multiple Myeloma.. Blood, 2006, 108, 242-242.	1.4	0
311	Perifosine, an Oral Bioactive Novel Akt Inhibitor, Induces In Vitro and In Vivo Antitumor Activity in Waldenstrom Macroglobulinemia.. Blood, 2006, 108, 2488-2488.	1.4	2
312	Clinical and Pathological Prognostic Markers for Survival in Adult Patients with Post-Transplant Lymphoproliferative Disorders (PTLD), BCL2 Is a Poor Prognostic Marker in PTLD.. Blood, 2006, 108, 2035-2035.	1.4	0
313	Multiple Myeloma With Amplification of Chr1q: Therapeutic Opportunity and Challenges. Frontiers in Oncology, 0, 12, .	2.8	2